A Bright Horizon: Staying Up To Date with New and Emerging Therapies For Atopic Dermatitis (Webcourse)
Credit(s): 1.00 (60 min)
Release Date: Apr 26, 2022
Expiration Date: Apr 26, 2023
MIPS Improvement Activity Under MACRA
Physicians – AMA PRA Category 1 Credit(s) ™
Physicians/ABIM MOC – ABIM MOC Point(s)
Approximately one-third of patients with atopic dermatitis (AD) have severe disease that requires systemic treatment directed at controlling immune responses. In recent years, novel therapies targeting the underlying pathophysiology of AD have been approved with many more emerging, but many clinicians lack familiarity with these new and emerging agents as well as related mechanisms of action and safety and efficacy profiles. Furthermore, clinicians often underestimate AD disease severity and the impact on patient’s quality of life (QoL), leading to undertreatment.
This activity “A Bright Horizon: Staying Up To Date with New and Emerging Therapies For Atopic Dermatitis” aims to provide allergists and dermatologists with up-to-date information on management of moderate to severe AD, including the health burden of uncontrolled disease, identification of patients with more severe disease who require treatment escalation, evidence-based use of newer targeted therapies, and how emerging therapies may impact AD management in the near term.
Jointly provided by the Potomac Center for Medical Education and Rockpointe
Patient Resources provided by
This activity is supported through an educational grant from Pfizer Inc.
Clicking Start Activity indicates that you have reviewed the CME/CE information for this activity
Mycobacterium Avium Complex: Guideline-based Management for a Deadly and Increasingly Prevalent Disease (Webcourse)
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.